期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 72, 期 6, 页码 1089-1098出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2012-201759
关键词
-
类别
资金
- INSERM
- Societe Francaise de Rhumatologie
- Association des Sclerodermiques de France
- Fondation pour la recherche Medicale
- Arthritis Foundation
- CMH [00000023728]
- Interdisciplinary Center of Clinical Research (IZKF) in Erlangen [A40]
- Deutsche Forschungsgesellschaft [DI 1537/1-1, DI 1537/2-1, DI 1537/4-1, AK 144/1-1, SCHE 1583/7-1]
- SERVIER
Objective To investigate the contribution of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of dermal fibrosis on gene inactivation and targeted molecular strategies. Methods Human skin expression of DNAM-1 was determined by immunohistochemistry. Mice deficient for DNAM-1 (dnam1(-/-)) and wild-type controls (dnam1(+/+)) were injected with bleomycin or NaCl. Infiltrating leucocytes, T cells, B cells and monocytes were quantified and inflammatory cytokines were measured in lesional skin of dnam1(-/-) and dnam1(+/+) mice. The anti-fibrotic potential of a DNAM-1 neutralising monoclonal antibody (mAb) was evaluated in the mouse model of bleomycin-induced dermal fibrosis. Results Overexpression of DNAM-1 was detected in the skin of patients with SSc (systemic sclerosis). Dnam1(-/-) mice were protected from bleomycin-induced dermal fibrosis with reduction of dermal thickening (75 +/- 5%, p=0.03), hydroxyproline content (46 +/- 8%, p=0.04) and myofibroblast counts (39 +/- 5%, p=0.01). Moreover, the number of T cells was significantly decreased in lesional skin of dnam1(-/-) mice (69 +/- 15%, p=0.0007). Dnam1(-/-) mice also displayed decreased levels of TNF-alpha and IL-6 in lesional skin. Consistent with the gene inactivation strategy, treatment of mice with DNAM-1 neutralising mAb prevented dermal fibrosis induced by bleomycin with reduction of dermal thickness (64 +/- 6%, p=0.002), hydroxyproline content (61 +/- 8%, p=0.004) and myofibroblast counts (83 +/- 12%, p=0.002). Conclusions An inactivation gene strategy showed that DNAM-1 exerts profibrotic effects by controlling T cell activation and cytokine release. A molecular targeted strategy confirmed that DNAM-1 neutralising mAb has potent antifibrotic properties, supporting the hypothesis that inhibition of DNAM-1 might be a promising new approach for the treatment of SSc and potentially other related fibrotic diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据